Investor News

11 August 2010

SUTHERLAND HEALTH GROUP PLC
(“Sutherland Health Group” or “the Company”)
PLUS Symbol: SHGP

FINAL RESULTS

The Board of Sutherland Health Group, a national supplier of patient hygiene, sexual health and diagnostic products to customers including the NHS, is pleased to announce its Final Results for the year ended 31 March 2010.

Highlights

• Sales growth of 6% to £956,509
• Gross profit increased by 18% to £500,523
• Gross margin increased from 46.9% to 52.3%
• Overheads reduced by 7% to £454,556
• Maiden profit of £29,336 (2009: loss of £81,912)

Commenting on today's news, Chairman, John French, said:

"The period to the 31 March 2010 has seen the Company reach a significant milestone in that we have achieved a maiden profit, turning a loss from the previous year of £81,912 into a profit of £29,336.

The new financial year has started well contributing to a performance that is ahead of last year in the first quarter. With the launch of the new gynaecology diagnostics still to come in the second half of our financial year, we look forward to updating shareholders on our continued progress"

The directors do not recommend payment of a final dividend.

The following information contained in this announcement has been extracted from audited
information.

---ENDS---

The Directors of the Issuer accept responsibility for this announcement.

Enquiries:
Sutherland Health Group plc
John French, Chairman
E: john@sutherlandhealth.com
T: 07836 722 482

Bridge Hall
Alex Benger
E: corpfin@bhcf.co.uk
T: 020 7337 9705

Bishopsgate Communications Ltd.
Maxine Barnes
E: shg@bishopsgatecommunications.com
T: 020 7562 3367

Notes to Editors:

Sutherland Health Group Plc is a national supplier of patient hygiene, sexual health and diagnostic products to the UK National Health Service (NHS) and other UK customers. Its aim is to supply innovative solutions to current health issues by studying current trends and working alongside leading professionals who also work within the health sector.

The company is committed to developing and marketing high quality brands and products that will benefit health professionals and consumers alike in many areas of health. The Group has established its own brands Condomania® Condoms, Sutherland® Lubricating Jelly and Vision® pregnancy diagnostics that have already become established within the NHS business.

The Company has also developed the Sutherland® patient hygiene range which is now on contract with NHS England and NHS Northern Ireland that can reduce the risk to patients of cross infection.

The Group is ISO and MHRA registered, and at present principally operates within the United Kingdom.

For further information on the Company visit www.sutherlandhealth.com

Back to top ^

Investor News archive